Fig. S1. REGN1500 reduces plasma levels of cholesterol, TG and NEFA in WT and Ldlr -/- mice. (A) WT

Transcription

1 Figure Legends for Supplementary Figures. Fig. S1. REGN15 reduces plasma levels of cholesterol, TG and NEF in WT and Ldlr -/- mice. () WT and Ldlr -/- mice were injected with control IgG or REGN15 (1 mg/kg) by tail vein (n=5 males/group, 11 week old). Four days after the injection, mice were fasted for 2 h at the end of the dark cycle, and blood was collected. Plasma lipid levels were measured enzymatically as described in the Methods. () Lipoprotein profiles of Ldlr -/ mice treated with control IgG or REGN15 P<.5, P<.1. Fig. S2. Decreased VLDL-TG secretion in ngptl3 -/- and REGN15-treated mice. () ngptl3 -/- mice and littermate controls (n=5 /group, 1-13 weeks old) were fed ad libitum and VLDL secretion was measured at the end of dark cycle as described in the Methods (Right). ngptl3 -/- mice and littermate controls were synchronized for 3 days with daytime fasting (7: am-7:pm) and nighttime refeeding (7: pm-7: am) (N=4-6 males/group, 6-9 weeks). On day 4, the livers were collected after a 24-hr fast (fasted) or at the end of the dark cycle (refed). Tissue lipid levels were measured as described in the Methods (Left). () VLDL-TG secretion is reduced in REGN5-treated Ldlr -/- mice. Ldlr -/- mice were treated exactly as described in Fig. 5. lood was drawn at the indicated time after Triton WR1339 (5 mg/kg) administration. Plasma was isolated and TG was measured (n=5 males/group, 1 week old). (C) VLDL-TG secretion in fasting mice. WT mice were fasted overnight and REGN15 or control antibody was injected at 8: am. Two hours later, Triton WR1339 (5 mg/kg) was injected into the tail vein and blood was collected and plasma TG levels measured at the indicated times. (D) REGN15 decreased VLDL-TG secretion in WT mice fed a fat-free diet. The feeding of WT mice was synchronized as described in the legend to Fig.5 except that the mice were refed a fat-free diet. On day 4, mice were refed at 7: am and injected with either control antibody or REGN15 at 9: am (n=5 male mice/group, 24 weeks old). Two hours after the injection, Triton WR1339 (5 mg/kg) was injected into 1

2 the tail vein. lood samples were drawn from the tail veins at the indicated time points. Plasma was isolated and TG was measured as described in the Method. P<.5, P<.1, P<.1 Fig. S3. Fatty acid uptake and clearance in REGN15-treated mice. () TG and NEF levels in REGN15-treated mice. () Uptake of NEF in tissues of mice treated with REGN15. WT mice were entrained to a synchronized feeding regimen as described in Fig. 5. On day 4, mice were refed at 7: am and injected 2 hours later with control antibody or REGN15 (1 mg/kg) (n=5 male mice/group, 1 weeks old). fter 2 hours, blood was collected and TG and NEF were measured. Mice were then injected with 1µci 3 H-bromopalmitate and 1µci of 14 C-palmitate. Tissues were collected and analyzed as described in Methods. (C) Tritiated palmitate turnover in REGN15-treated mice. Tritiatedpalmitate complexed with fatty acid free S was infused into the tail vein of the mice over 5 min as described in the Methods. The appearance of radioactivity was monitored in blood samples obtained every min for 7 min. 2

3 Figure S1 Triglyceride (µg/fraction) WT Ldlr -/- WT Ldlr -/- WT Ldlr-/- Cholesterol (mg/dl) VLDL LDL HDL Cholesterol (µg/fraction) 4 NEF (meq/l) 8 VLDL LDL HDL po-48 (.U) Fractions po-1 (.U) Fractions

4 Figure S /+ ngptl3 -/- Hepatic Triglyceride (mg/g) 8 4 +/+ ngptl3 -/- C D E Fasted Refed

5 Figure S3 Triglyceride (mg/dl) romopalmitate Uptake (dpm x 1 3 /1 mg) NEF (meq/l) Heart Liver WT T Muscle Lung Palmitate Uptake (dpm x 1 3 /1 mg) C 14 C-Palmitate (dpm/5 µl plasma) Heart Liver WT T Muscle Lung anti-ngptl Infuse